|
IC50: Noncompetitively inhibit histone acetyltransferase (HAT) activity in prostate cancer with an IC50 value of about 5.0 M.
Anacardic acid (AA) is commonly regarded as a non-specific HAT inhibitor of p300. Meanwhile, it regulates the activity and expression of several other crucial enzymes including NFκB kinase, lipoxygenase (LOX-1), xanthine oxidase, tyrosinase and ureases. Therefore, this compound exerts anti-oxidation, anti-inflammation and anti-tumor activities in vitro and in vivo. [1]
In vitro: LNCaP, a classical metastatic prostate adenocarcinoma cell line, was adopted to study the effect of AA on cell growth, cycles and apoptosis. It was found that 125 M AA significantly inhibited LNCaP cell proliferation. In addition, the G1/S cell cycles arrest and the apoptosis of LNCaP cell was induced. Further mechanistic study suggested that AA induced cell apoptosis via suppressing p300. [1]
In vivo: Diesel exhaust particle- (DEP-) induced lung inflammation model was established to study the effect of AA on inflammation in mice. Ten days before DEP-instillation stimulation, mice were orally pretreated with 50, 150, or 250 mg/kg of AA for thirty days. All doses of AA ameliorated activities of oxidative enzymes. Moreover, 50 mg/kg of AA significantly decreased the expression level of tumor necrosis factor in lung. [2]
Clinical trial: So far, no clinical study has been conducted yet.
|